Ligand (LGND) news

Orchestra Biomed - Primary endpoint data to be submitted for presentation at cardiovascular conference in Q2 2027

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has outlined a timeline for the submission of primary endpoint data from its BACKBEAT Trial, which is evaluating AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. The company, in collaboration with Medtronic,…

Arecor Therapeutics - Close of accelerated bookbuild to new orders

Arecor Therapeutics PLC (AIM: AREC) has announced the close of an accelerated bookbuild to new orders, raising capital through the monetisation of royalty and technology access fee streams from its portfolio assets. The company has entered into a royalty financing agreement with Ligand…

Arecor Therapeutics - Launches fundraising to raise up to GBP 5.13 mln

Arecor Therapeutics PLC (AIM:AREC) has announced plans to launch a fundraising initiative aimed at raising up to GBP 5.13 million to support its ongoing development programs and operational requirements. The company, which focuses on diabetes and cardiometabolic treatments, has previously secured…

Ligand Pharmaceuticals Incorporated - Commits up to $6 mln in Series C financing

Ligand Pharmaceuticals Incorporated: Citigroup raises target price to $397 from $390

Citigroup analyst Yigal Nochomovitz has raised the price target for Ligand Pharmaceuticals (LGND) to $276 from $270, maintaining a 'Buy' rating for the biopharmaceutical company. This adjustment reflects a 2.22% increase in the firm’s target price. The move follows a series of positive analyst…